{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:24:04Z","timestamp":1792567444809,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00198-022-06610-9","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T12:03:57Z","timestamp":1668859437000},"page":"291-297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Discontinuation of denosumab in men with prostate cancer"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7252-8128","authenticated-orcid":false,"given":"Anne Sophie","family":"S\u00f8lling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-3523","authenticated-orcid":false,"given":"Torben","family":"Harsl\u00f8f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Kongsbak","family":"Brockstedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7199","authenticated-orcid":false,"given":"Bente","family":"Langdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"issue":"5","key":"6610_CR1","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL et al (2012) Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov 11(5):401\u2013419","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"6610_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"2","key":"6610_CR3","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222\u2013229","journal-title":"Bone"},{"issue":"4","key":"6610_CR4","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"issue":"27(8S)","key":"6610_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/RHU.0000000000000979","volume":"1","author":"P Anagnostis","year":"2021","unstructured":"Anagnostis P et al (2021) Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases. J Clin Rheumatol 1(27(8S)):581\u2013584","journal-title":"J Clin Rheumatol"},{"key":"6610_CR6","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.bonr.2020.100267","volume":"12","author":"A Anastasilakis","year":"2020","unstructured":"Anastasilakis A et al (2020) Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation. Bone Rep 12:100267","journal-title":"Bone Rep"},{"issue":"12","key":"6610_CR7","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD et al (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Min Res 34(12):2220\u20132228","journal-title":"J Bone Min Res"},{"issue":"10","key":"6610_CR8","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS et al (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Min Res 35(10):1858\u20131870","journal-title":"J Bone Min Res"},{"issue":"7","key":"6610_CR9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.cell.2021.03.010","volume":"184","author":"M McDonald","year":"2021","unstructured":"McDonald M et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184(7):1940","journal-title":"Cell"},{"key":"6610_CR10","unstructured":"Schaeffer M et al (2022) NCCN clinical practice guidelines in Oncology (NCCN Guidelines) Prostate Cancer version 3.2022. J Natl Compr Canc Netw. Avaliable at https:\/\/www.nccn.org\/"},{"issue":"2","key":"6610_CR11","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N et al (2005) Androgen deprivation therapy for prostate cancer\u2019. JAMA 294(2):238\u2013244","journal-title":"JAMA"},{"issue":"12","key":"6610_CR12","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL et al (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90(12):6410\u20136417","journal-title":"J Clin Endocrinol Metab"},{"key":"6610_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB et al (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164","journal-title":"N Engl J Med"},{"issue":"3","key":"6610_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.juro.2010.04.068","volume":"184","author":"SMH Alibhai","year":"2010","unstructured":"Alibhai SMH et al (2010) Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 184(3):918\u2013924","journal-title":"J Urol"},{"issue":"8","key":"6610_CR15","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745\u2013755","journal-title":"N Engl J Med"},{"issue":"6","key":"6610_CR16","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.juro.2009.08.048","volume":"182","author":"M Smith","year":"2009","unstructured":"Smith M et al (2009) Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 182(6):2670\u20132675","journal-title":"J Urol"},{"issue":"7 Suppl","key":"6610_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1403494811399956","volume":"39","author":"LC Thygesen","year":"2011","unstructured":"Thygesen LC et al (2011) Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation, and archiving. Scand J Public Health 39(7 Suppl):12\u201316","journal-title":"Scand J Public Health"},{"issue":"9","key":"6610_CR18","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P et al (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36(9):1717\u20131728","journal-title":"J Bone Miner Res"},{"key":"6610_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/bcj.2015.71","volume":"5","author":"JM Piot","year":"2015","unstructured":"Piot JM et al (2015) Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance. Blood Cancer J 5:345","journal-title":"Blood Cancer J"},{"issue":"1","key":"6610_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","volume":"179","author":"E Gonzalez-Rodriguez","year":"2020","unstructured":"Gonzalez-Rodriguez E et al (2020) Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat 179(1):153\u2013159","journal-title":"Breast Cancer Res Treat"},{"key":"6610_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"issue":"7","key":"6610_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS et al (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Min Res 36(7):1245\u20131254","journal-title":"J Bone Min Res"},{"issue":"7","key":"6610_CR23","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J et al (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains\u2019. J Bone Min Res 35(7):1207\u20131215","journal-title":"J Bone Min Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06610-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06610-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:45:56Z","timestamp":1674477956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06610-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6610"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06610-9","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Torben Harsl\u00f8f received lecture fees from Amgen, Astra Zeneca, UCB, and Eli Lilly. Bente Langdahl has received research funding to her institution from Amgen and Novo Nordisk. Bente Langdahl serves on advisory boards and speaker\u2019s bureau for Amgen, UCB, Gilead, Astra-Zenica, and Gedeon-Richter. Helle Kongsbak Brockstedt received lecture fees from Amgen. Anne Sophie S\u00f8lling received lecture fees from Amgen and Gedeon-Richter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}